Accrued expenses consisted of the following: | | | | | | | | | December 31, | (in thousands) | | 2025 | | 2024 | Product sales provisions(1) | | $ | — | | $ | 2,107 | Research and development(2) | | | 547 | | | 6,622 | Professional services | | | 379 | | | 491 | Other | | | 15 | | | 52 | Total accrued expenses | | $ | 941 | | $ | 9,272 |
| (1) | Comprised primarily of liabilities related to product returns associated with the MST Franchise. |
| (2) | Comprised primarily of accruals related to fees for contract research organizations, investigative sites, and other service providers that assist in conducting preclinical research studies and clinical trials. |
|